Weight loss injections, particularly Ozempic, have gained immense popularity for their effectiveness in promoting weight loss, originally designed for managing type 2 diabetes.

The active ingredient, semaglutide, influences the appetite center in the brain, reduces hunger, and slows gastric emptying, enabling individuals to adhere to strict diets.

Reports indicate a significant transformation in the purchasing and eating habits of users, which is now observable at the macroeconomic level, especially impacting the food and hospitality industries.

Users of Ozempic have reported a marked decrease in appetite, with many forgetting to eat or finding previously favored foods unappealing.

There has been a notable decline in cravings for high-fat, high-sugar, and heavily processed foods.

Furthermore, snacking, late-night eating, and instances of overeating have diminished significantly among users.

This behavioral change is clearly reflected in shopping baskets, where there is a noticeable decrease in the purchase of:

- Sweets
- Ready-made meals
- Carbonated drinks
- Snacks

Conversely, the consumption of fresh vegetables, lean meats, and healthier alternatives may see a relative increase, albeit in smaller quantities.

Additionally, one of the most pronounced trends is the drop in frequency of restaurant visits among Ozempic users.

Many are not only eating less but are also less inclined to engage in experiential dining, social dinners, or indulge in fast food, as they find portion sizes excessively large.

Leaving half of a meal uneaten is often viewed as wasteful.

This behavioral shift is significantly impacting fast-food chains, which are increasingly reporting downturns in revenue throughout the United States.

In particular, mid-range urban restaurants may face adverse effects from this trend.

Conversely, establishments that offer smaller portions and health-conscious low-calorie meals may experience a surge in popularity.